Two Stocks, Two Lessons: MRNA and ACMR on FDA Vote Day
A Real-Time Day Trading Analysis — June 18, 2026
The Setup: Why These Two Stocks Were on My Radar
Every morning I run a custom E*TRADE screener filtering for NASDAQ and NYSE stocks between $15 and $100, with Mid/Large/Mega cap market caps and a price change of 5% or more over the prior day. On June 18, 2026, two names jumped off the screen immediately — Moderna (MRNA) and ACM Research (ACMR). Both had strong momentum stories, strong catalysts, and institutional support. But the way each traded that morning told completely different stories — and both delivered a masterclass in why rules-based trading protects you from yourself.
MRNA — Moderna Inc. (NASDAQ)
The Setup: America’s First mRNA Flu Vaccine Goes to FDA Panel
Moderna had been on a 5-day run of +34% heading into June 18, closing the prior session at $61.80. The reason was unmistakable: the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) was scheduled to meet on June 18 to vote on mFlusiva (mRNA-1010) — Moderna’s experimental mRNA-based influenza vaccine and potentially the first of its kind to receive U.S. approval.
The pre-meeting FDA briefing documents were constructive. Staff identified no major deficiencies in the submission and confirmed that mFlusiva met all pre-specified success criteria in its Phase III trial — demonstrating relative vaccine efficacy of 26.6% against RT-PCR-confirmed influenza compared to a standard-dose comparator in a study of 40,000 participants. Analysts noted that if approved, mFlusiva would be the first mRNA-based seasonal flu vaccine in United States history, with a PDUFA final decision date set for August 5, 2026.
My entry trigger for MRNA was set at $63.00 — confirmed at 9:45 AM CDT, with a hard stop at $59.00 and targets of $66 and $69. Because of the binary FDA vote risk, I also built in an earlier hard exit of 11:30 AM CDT — well before the committee vote could deliver a surprise result.
What Actually Happened
The tape told the whole story:
- 8:30 AM CDT: MRNA opened at $63.96 on 859,570 shares — a massive, euphoric open driven by pre-vote optimism
- 8:33 AM CDT: Stock hit a session high of $67.74 on 96,000 shares — the market pricing in a positive vote before it happened
- 8:46 AM CDT: Reality hit. MRNA crashed from $63.13 to $61.80 in one minute on 67,000 shares — a $5.94 drop from the high in just 20 minutes
- 9:11 AM CDT: Stock touched $60.82 — below the prior day’s close — on heavy institutional selling
- 9:45 AM CDT (entry window): MRNA was trading at $62.44 — below my $63.00 trigger
The trigger never fired. No trade.
The Lesson
MRNA showed exactly why binary event trades require extraordinary discipline. The stock opened 3.5% above my trigger, ripped to $67.74 in the first three minutes, then gave back everything in 20 minutes before I even had the chance to consider entering. Traders who chased the open print at $63.96 were underwater by $3+ within the hour. Traders who chased the $67.74 high were down nearly $7 per share at the worst moment of the session.
The $63.00 trigger at 9:45 AM CDT was the gate that protected me from both scenarios. When the stock was below the trigger at the entry window — that was the tape saying “not today.” I listened.
Rule reinforced: On FDA vote days and binary catalyst events, move the hard exit earlier. Pre-vote euphoria is frequently followed by “sell the news” regardless of outcome. The trigger rule is not optional — it’s protection.
ACMR — ACM Research Inc. (NASDAQ)
The Setup: Semiconductor Equipment Momentum — AI Demand Surge
ACM Research had been one of the strongest momentum stories in the semiconductor equipment space, closing the prior session at $96.19 — up +20% over five days and +286% over the prior 52 weeks. The catalyst stack was deep: Q1 revenue of $231.3M beat the $215.7M consensus by a wide margin, non-GAAP EPS of $0.34 crushed the $0.20 Street estimate, and newly signed orders at ACM Shanghai grew 65% year-over-year. Roth Capital had raised their price target to $100, and management reaffirmed 2026 revenue guidance of $1.08–$1.175 billion — implying 20–30% annual growth driven by AI chip demand.
My entry trigger for ACMR was set at $97.50 — confirmed at 9:45 AM CDT, with a hard stop at $93.00 and targets of $100 and $104.
What Actually Happened
ACMR never gave me the chance to trade it — and that was the correct outcome:
- 8:30 AM CDT: ACMR opened at $102.95 — already $6.76 above the prior close
- That’s a +7% gap at the open — well above my “4% premarket move” adjustment rule
- By 9:08 AM CDT, ACMR hit a session high of $106.00
- Current price at the time of analysis: $104.75 (+8.90%)
But here’s what the tape was also showing: most 1-minute candles were trading 200 to 4,000 shares. For a $104 stock, that is dangerously thin volume. My system requires 1-minute candle averages of 10,000+ shares for a clean intraday entry and exit. ACMR failed that test decisively.
Additionally, at $104.75, ACMR was trading above my $100 price ceiling filter — which had already eliminated it from consideration before I even opened the chart.
Two filters fired. No trade. Correct outcome.
The Lesson
ACMR illustrates two important points working together:
First — the price filter is there for a reason. Stocks above $100 per share carry higher per-share risk, wider bid/ask spreads, and require more capital for even a single-share position. My system caps at $100 for all of these reasons. ACMR gapped right through that ceiling at the open — the filter did its job automatically.
Second — volume matters as much as price direction. A stock up +8.90% in a session sounds exciting. But if the 1-minute candles are averaging 500 shares, getting in AND out cleanly at your target price becomes a game of luck, not skill. Thin volume means wide spreads, slippage, and the risk of being “stuck” in a position when you need to exit. ACMR’s semiconductor momentum story was real and the price move was genuine — but it was not a tradeable intraday setup under disciplined rules.
Rule reinforced: A great story does not equal a tradeable setup. Volume confirmation at the 1-minute level is a non-negotiable gate before any entry. When a stock gaps far above your price filter ceiling at the open, remove it from the day’s list immediately.
The Bigger Picture: What June 18 Taught Me
On a day with two high-profile catalysts — an FDA advisory vote and a semiconductor breakout — my system produced zero trades and zero losses.
That may sound like a missed opportunity. It wasn’t.
- MRNA opened at $63.96, spiked to $67.74, then crashed to $60.82 — anyone who chased the open was underwater by $3 to $7 per share within the hour
- ACMR gapped above my filter at the open and traded on thin volume all morning — not a clean intraday setup despite the strong price move
The triggers, the filters, and the volume checks did exactly what they were designed to do: protect capital from impulsive decisions on exciting news days. That discipline — sitting on hands when the setup doesn’t confirm — is what separates traders who survive from traders who don’t.
Capital preserved is capital available for the next setup. And the next setup will come.
My Day Trading System — Quick Reference
For those interested in the framework behind this analysis:
| Rule | Setting |
|---|---|
| Exchange | NASDAQ / NYSE only |
| Price Range | $15.00 – $100.00 |
| Market Cap | Mid / Large / Mega cap only |
| Avg Daily Volume | 5M+ shares |
| 1-Min Candle Volume | 10,000+ shares avg |
| Entry Window | 9:45 – 10:15 AM CDT |
| Observation Phase | 8:30 – 9:45 AM CDT (no trades) |
| Hard Exit | 1:30 PM CDT |
| Flat Deadline | 2:00 PM CDT |
| Premarket Gap Rule | 4%+ move = adjust or skip |
| Binary Event Rule | Earlier exit (11:30 AM CDT) |
The philosophy draws on the core principles of Jesse Livermore (tape reading, patience), Paul Tudor Jones (capital protection), Richard Dennis (mechanical rules, remove emotion), and George Soros (position only when the setup is confirmed, exit fast when wrong).
This post is for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. Day trading involves substantial risk of loss. Always trade only with capital you can afford to lose entirely.